SCHEMBL4009012

SCHEMBL4009012

CS(=O)(=O)c1ccccc1NS(=O)(=O)c1ccc2[nH]nc(O)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ GFER P55789 1/20 0.46
▸ POLB P06746 7/20 0.44
▸ NTRK1 P04629 1/20 0.42
▸ MET P08581 1/20 0.42
▸ NTRK2 Q16620 1/20 0.42
▸ MAP2K4 P45985 3/20 0.42
▸ MAP2K7 O14733 1/20 0.42
▸ MAPT P10636 5/20 0.40
▸ TP53 P04637 4/20 0.40
▸ LMNA P02545 3/20 0.40
▸ TDP1 Q9NUW8 6/20 0.40
▸ PTGES2 Q9H7Z7 2/20 0.40
▸ CCR2 P41597 1/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014544 0.87 MAPT (0.43) KMT2AMEN1GAAGFERPOLB
SCHEMBL4017635 0.86 CCR2 (0.42) KMT2AMEN1GAAGFERPOLB
SCHEMBL4008742 0.86 PTGES2 (0.45) KMT2AMEN1GAAGFERPOLB
SCHEMBL4008442 0.85 MAP2K4 (0.48) MAP2K4MAP2K7MAPTPTGES2
SCHEMBL4009500 0.84 BRAF (0.45) KMT2AMEN1GAAGFERPOLB
SCHEMBL4013522 0.84 POLB (0.52) KMT2APOLBNTRK1MAPTTP53
SCHEMBL4007219 0.83 TP53 (0.43) KMT2AMEN1GAAGFERPOLB
SCHEMBL4009872 0.81 CSNK2A1 (0.55) KMT2AGAAPOLB
SCHEMBL4006558 0.81 CDK7 (0.50) KMT2APOLBMAPTLMNATDP1
SCHEMBL4013164 0.79 ITK (0.46) KMT2AMEN1NTRK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7473701-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2009-01-06 — — US disclosed
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-03-17 — — US disclosed
US-6858638-B2 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2005-02-22 — — US disclosed
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use AVENTIS PHARMA S.A. (FR) 2004-06-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106667-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 KMT2A 1089/4885MEN1 2247/4885GAA 2692/4885
US-20050059722-A1 Substituted indazoles, compositions containing them, method of production and use ABL1, CDK3, CILK1 KMT2A 1222/4885MEN1 2443/4885GAA 2476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback